Cargando…

Surgical cytoreduction of the primary tumor reduces metastatic progression in a mouse model of prostate cancer

Metastatic prostate cancer (mPCa) is one of the most prevalent cancers in men worldwide. The main cause of death in these patients is androgen-resistant metastatic disease. Surgery of the primary tumor has been avoided in these patients as there is no strong evidence that supports a beneficial effec...

Descripción completa

Detalles Bibliográficos
Autores principales:	CIFUENTES, FEDERICO F., VALENZUELA, RODRIGO H., CONTRERAS, HÉCTOR R., CASTELLÓN, ENRIQUE A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2015
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722890/ https://www.ncbi.nlm.nih.gov/pubmed/26503286 http://dx.doi.org/10.3892/or.2015.4319

Ejemplares similares

Development of an orthotopic model of human metastatic prostate cancer in the NOD-SCIDγ mouse (Mus musculus) anterior prostate
por: CIFUENTES, FEDERICO F., et al.
Publicado: (2015)

Impact of tumor cytoreduction in metastatic prostate cancer
por: Sow, Yaya, et al.
Publicado: (2019)

Functional characteristics of cancer stem cells and their role in drug resistance of prostate cancer
por: CASTILLO, VIVIANA, et al.
Publicado: (2014)

Cytoreductive surgery for men with metastatic prostate cancer
por: Katelaris, Nikolas, et al.
Publicado: (2016)

Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer
por: Babst, Christa, et al.
Publicado: (2022)

An Updated Systematic and Comprehensive Review of Cytoreductive Prostatectomy for Metastatic Prostate Cancer
por: Yanagisawa, Takafumi, et al.
Publicado: (2023)

Cancer Stemness/Epithelial–Mesenchymal Transition Axis Influences Metastasis and Castration Resistance in Prostate Cancer: Potential Therapeutic Target
por: Castellón, Enrique A., et al.
Publicado: (2022)

AB056. Cytoreductive radical prostatectomy for men with oligo-metastatic prostate cancer
por: Liu, Shengjie, et al.
Publicado: (2017)

The transcription factor ZEB1 promotes chemoresistance in prostate cancer cell lines
por: Orellana-Serradell, Octavio, et al.
Publicado: (2019)

Primary Tumor Resection Decelerates Disease Progression in an Orthotopic Mouse Model of Metastatic Prostate Cancer
por: Linxweiler, Johannes, et al.
Publicado: (2022)

The transcription factor ZEB1 promotes an aggressive phenotype in prostate cancer cell lines
por: Orellana-Serradell, Octavio, et al.
Publicado: (2018)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

SNAIL transcription factor increases the motility and invasive capacity of prostate cancer cells
por: OSORIO, LUIS A., et al.
Publicado: (2016)

Secondary surgical cytoreduction needs to be assessed taking into account surgical technique, completeness of cytoreduction, and extent of disease
por: Segura-Sampedro, Juan José, et al.
Publicado: (2020)

Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche
por: Sánchez, Catherine A., et al.
Publicado: (2015)

Survival Outcomes and Prognostic Analysis Following Greater Cytoreductive Radiotherapy in Patients With Metastatic Prostate Cancer
por: Zhang, Zitong, et al.
Publicado: (2020)

Secreted protein acidic and rich in cysteine (SPARC) induces epithelial-mesenchymal transition, enhancing migration and invasion, and is associated with high Gleason score in prostate cancer
por: López-Moncada, Fernanda, et al.
Publicado: (2019)

A rapid progression of new metastatic lesion after cytoreductive nephrectomy: A case report
por: Steven, Steven, et al.
Publicado: (2021)

Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer
por: Yuh, Bertram E., et al.
Publicado: (2019)

Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience
por: Liu, Yang, et al.
Publicado: (2021)

Emerging role of cytoreductive prostatectomy in patients with metastatic disease
por: Jaber, Yasmeen, et al.
Publicado: (2018)

The transcriptional factor ZEB1 represses Syndecan 1 expression in prostate cancer
por: Farfán, Nancy, et al.
Publicado: (2018)

Increased SNAIL expression and low syndecan levels are associated with high Gleason grade in prostate cancer
por: POBLETE, CRISTIAN E., et al.
Publicado: (2014)

Cytoreductive Nephrectomy and Nephrectomy/Complete Metastasectomy for Metastatic Renal Cancer
por: Russo, Paul, et al.
Publicado: (2007)

The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma
por: Umbreit, Eric C., et al.
Publicado: (2021)

The Evolving Landscape of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma
por: Studentova, Hana, et al.
Publicado: (2023)

Role of aggressive surgical cytoreduction in advanced ovarian cancer
por: Chang, Suk-Joon, et al.
Publicado: (2015)

Trends in extent of surgical cytoreduction for patients with ovarian cancer
por: Wong, Deanna H., et al.
Publicado: (2021)

The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry
por: Lumen, Nicolaas, et al.
Publicado: (2021)

The role of cytoreductive radical prostatectomy and lymph node dissection in bone‐metastatic prostate cancer: A population‐based study
por: Zhai, Tingshuai, et al.
Publicado: (2023)

Peritoneal Metastatic Goblet-Cell Carcinoid Tumor Treated With Cytoreductive Surgery and Intraperitoneal Chemotherapy
por: Youn, Sang Il, et al.
Publicado: (2015)

Laparoscopic Cytoreduction for Primary Advanced Ovarian Cancer
por: Fanning, James, et al.
Publicado: (2010)

Conditional survival of metastatic clear cell renal cell carcinoma: How prognosis evolves after cytoreductive surgery of primary tumor
por: Shen, Haixiang, et al.
Publicado: (2021)

SPARC Induces E-Cadherin Repression and Enhances Cell Migration through Integrin αvβ3 and the Transcription Factor ZEB1 in Prostate Cancer Cells
por: López-Moncada, Fernanda, et al.
Publicado: (2022)

Weekly induction intraperitoneal chemotherapy after primary surgical cytoreduction in patients with advanced epithelial ovarian cancer
por: Yu Zang, Rong, et al.
Publicado: (2006)

Response to Letter to the Editor From Berruti et al: “Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients’ Survival”
por: Srougi, Victor, et al.
Publicado: (2022)

Proteomic characterization of primary and metastatic prostate cancer reveals reduced proteinase activity in aggressive tumors
por: Li, Qing Kay, et al.
Publicado: (2021)

Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression
por: Jethwa, Krishan R., et al.
Publicado: (2016)

The efficacy of cytoreductive surgery for oligometastatic prostate cancer: a meta-analysis
por: Cheng, Bisheng, et al.
Publicado: (2021)

Is Cytoreductive Nephrectomy Still a Standard of Care in Metastatic Renal Cell Carcinoma?
por: Renner, Alex, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_eafbfj33ha6ghjeun9jonrl9df